Skip to content

ORAMED PHARMACEUTICALS INC.: 10-Q filed 2014-04-10

What ORAMED PHARMACEUTICALS INC. reported in its quarterly report filed 2014-04-10 (fiscal Q2 2014): 25 published measures, 90 facts as tagged in accession 0001178913-14-001274.

This filing

Form
10-Q (quarterly report)
Filed
2014-04-10
Fiscal period
fiscal Q2 2014
Accession
0001178913-14-001274 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ORAMED PHARMACEUTICALS INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2014-02-2823,709,956USD
At 2013-08-318,660,182USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2014-02-2823,327,715USD
At 2013-08-318,130,775USD
At 2012-08-313,778,013USD
At 2011-08-313,723,916USD
At 2010-08-31830,272USD
At 2009-08-312,746,192USD
At 2008-08-314,593,060USD
At 2007-08-31513,131USD
At 2002-04-1153,700USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2014-02-283,252,911USD
At 2013-08-312,272,228USD
At 2013-02-282,039,905USD
At 2012-08-314,430,740USD
At 2011-08-311,513,365USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2013-12-01 to 2014-02-28-1,114,842USD90
2013-09-01 to 2014-02-28-2,239,162USD181
2002-04-12 to 2014-02-28-24,362,751USD4341
2012-09-01 to 2013-08-31-4,231,812USD365
2012-12-01 to 2013-02-28-1,225,874USD90
2012-09-01 to 2013-02-28-2,184,627USD181
2011-09-01 to 2012-08-31-3,344,478USD366
2010-09-01 to 2011-08-31-1,561,245USD365
2009-09-01 to 2010-08-31-2,977,376USD365
2008-09-01 to 2009-08-31-2,760,474USD365
2007-09-01 to 2008-08-31-2,769,271USD366
2002-04-12 to 2007-08-31-4,478,917USD1968

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2013-09-01 to 2014-02-28-2,230,938USD181
2002-04-12 to 2014-02-28-16,511,659USD4341
2012-09-01 to 2013-02-28-2,065,590USD181

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2013-09-01 to 2014-02-289,379USD181
2002-04-12 to 2014-02-28141,370USD4341

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2013-09-01 to 2014-02-2816,494,983USD181
2002-04-12 to 2014-02-2837,811,415USD4341
2012-09-01 to 2013-02-281,450,936USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2013-09-01 to 2014-02-28-13,293,344USD181
2002-04-12 to 2014-02-28-18,028,616USD4341
2012-09-01 to 2013-02-28-1,750,018USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2014-02-28-24,362,751USD
At 2013-08-31-22,123,589USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2002-04-12 to 2014-02-2835,714USD4341

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2014-02-2812,164USD
At 2013-08-315,768USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2013-09-01 to 2014-02-28333,137USD181
2002-04-12 to 2014-02-286,023,643USD4341
2012-09-01 to 2013-02-28441,084USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2013-12-01 to 2014-02-28-1,185,586USD90
2013-09-01 to 2014-02-28-2,353,823USD181
2002-04-12 to 2014-02-28-24,786,863USD4341
2012-12-01 to 2013-02-28-1,259,830USD90
2012-09-01 to 2013-02-28-1,991,669USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2014-02-2823,686,895USD
At 2013-08-318,644,276USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2014-02-28349,819USD
At 2013-08-31498,193USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2013-12-01 to 2014-02-28673,334USD90
2013-09-01 to 2014-02-281,423,844USD181
2002-04-12 to 2014-02-2813,228,332USD4341
2012-12-01 to 2013-02-28748,996USD90
2012-09-01 to 2013-02-281,141,622USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2014-02-289,776,167shares
At 2013-08-317,937,872shares
At 2013-01-107,200,000shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2014-02-28846,985USD
At 2013-08-31303,403USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2014-02-28245,596USD
At 2013-08-3190,103USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2013-12-01 to 2014-02-28-1,114,842USD90
2013-09-01 to 2014-02-28-2,239,162USD181
2002-04-12 to 2014-02-28-24,327,037USD4341
2012-12-01 to 2013-02-28-1,225,874USD90
2012-09-01 to 2013-02-28-2,184,627USD181

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2013-12-01 to 2014-02-28-602,030USD90
2013-09-01 to 2014-02-28-1,695,580USD181
2002-04-12 to 2014-02-28-23,515,766USD4341
2012-12-01 to 2013-02-28-1,217,234USD90
2012-09-01 to 2013-02-28-1,940,119USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2013-12-01 to 2014-02-28512,252USD90
2013-09-01 to 2014-02-28929,979USD181
2002-04-12 to 2014-02-2811,123,655USD4341
2012-12-01 to 2013-02-28510,834USD90
2012-09-01 to 2013-02-28850,047USD181

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2013-09-01 to 2014-02-282,983USD181
2002-04-12 to 2014-02-28129,206USD4341
2012-09-01 to 2013-02-282,899USD181

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2013-09-01 to 2014-02-2814,887,085USD181

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2013-09-01 to 2014-02-28-148,374USD181
2002-04-12 to 2014-02-28302,567USD4341
2012-09-01 to 2013-02-28-175,031USD181

Inspect the source

Entity
ORAMED PHARMACEUTICALS INC. / CIK 0001176309
Captured
2026-09-20T07:44:51.277Z
SEC response SHA-256
4de2fa61f6e99a9334450df93c3a54e105e138fae12a8b631b4bdc95f4c98422

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001176309.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))